💊Pharmacology for Nurses Unit 11 – Parkinson's and MS Drug Treatments

What's the Deal with Parkinson's and MS?

• Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting movement, balance, and coordination
• Caused by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain involved in motor control
• Symptoms include tremors, rigidity, bradykinesia (slowness of movement), and postural instability
• Multiple sclerosis (MS) is an autoimmune disease that attacks the protective myelin sheath surrounding nerve fibers in the central nervous system (brain and spinal cord)
  • Leads to inflammation, scarring, and damage to the myelin, disrupting nerve impulse transmission
• MS symptoms vary widely but can include muscle weakness, numbness, tingling, vision problems, fatigue, and difficulty with coordination and balance
• Both PD and MS are chronic conditions that significantly impact a person's quality of life and require ongoing management with medications and supportive care

Key Players: Neurotransmitters and Pathways

• Dopamine is a crucial neurotransmitter involved in the regulation of movement, reward, and motivation
  • In PD, the loss of dopamine-producing neurons leads to an imbalance in the basal ganglia, a group of brain structures that control movement
• Acetylcholine is another neurotransmitter that plays a role in PD
  • An imbalance between dopamine and acetylcholine contributes to the motor symptoms of PD
• Glutamate is an excitatory neurotransmitter that is thought to play a role in the damage to myelin in MS
  • Excessive glutamate release can lead to excitotoxicity, causing damage to neurons and oligodendrocytes (cells that produce myelin)
• The nigrostriatal pathway is a dopaminergic pathway that connects the substantia nigra to the striatum (part of the basal ganglia)
  • This pathway is particularly affected in PD, leading to the characteristic motor symptoms
• The immune system, particularly T cells and B cells, plays a central role in the pathogenesis of MS
  • Autoreactive T cells cross the blood-brain barrier and attack the myelin sheath, leading to inflammation and damage

Parkinson's Meds: The Usual Suspects

• Levodopa (L-dopa) is a precursor to dopamine that can cross the blood-brain barrier and be converted to dopamine in the brain
  • Often combined with carbidopa (Sinemet) to prevent peripheral conversion of L-dopa to dopamine, reducing side effects like nausea and vomiting
• Dopamine agonists (pramipexole, ropinirole) directly stimulate dopamine receptors, mimicking the action of dopamine
  • Can be used as monotherapy in early PD or as an adjunct to L-dopa in advanced stages
• Monoamine oxidase B (MAO-B) inhibitors (selegiline, rasagiline) block the enzyme that breaks down dopamine, increasing its availability in the brain
• Catechol-O-methyltransferase (COMT) inhibitors (entacapone, tolcapone) block the enzyme that metabolizes L-dopa, extending its duration of action
  • Often used in combination with L-dopa/carbidopa to manage wearing-off effects
• Anticholinergics (trihexyphenidyl, benztropine) block the action of acetylcholine, helping to restore the balance between dopamine and acetylcholine in PD
  • Primarily used to manage tremor in younger patients

MS Treatments: Taming the Immune System

• Disease-modifying therapies (DMTs) aim to reduce the frequency and severity of MS relapses and slow the progression of disability
• Interferon beta (Avonex, Rebif, Betaseron) is a cytokine that modulates the immune response and has anti-inflammatory effects
  • Reduces the number of relapses and the development of new lesions on MRI
• Glatiramer acetate (Copaxone) is a synthetic peptide that mimics myelin basic protein
  • Thought to shift the immune response from pro-inflammatory to anti-inflammatory, reducing damage to myelin
• Natalizumab (Tysabri) is a monoclonal antibody that blocks the entry of immune cells into the central nervous system
  • Highly effective in reducing relapses and disability progression but carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection
• Fingolimod (Gilenya) is an oral medication that sequesters lymphocytes in lymph nodes, preventing their entry into the central nervous system
• Dimethyl fumarate (Tecfidera) is an oral medication with immunomodulatory and neuroprotective properties
  • Reduces the number of relapses and the development of new lesions on MRI

How These Drugs Work Their Magic

• Parkinson's medications primarily work by restoring the balance of dopamine in the brain
  • L-dopa is converted to dopamine, dopamine agonists stimulate dopamine receptors, and MAO-B and COMT inhibitors prevent the breakdown of dopamine
• Anticholinergics in PD help to restore the balance between dopamine and acetylcholine, which is disrupted due to the loss of dopamine-producing neurons
• MS treatments focus on modulating the immune response to reduce inflammation and damage to the myelin sheath
  • Interferons and glatiramer acetate shift the immune response towards an anti-inflammatory state
  • Natalizumab and fingolimod prevent immune cells from entering the central nervous system, reducing inflammation and damage
• Some MS treatments, like dimethyl fumarate, also have neuroprotective properties that may help to preserve neuronal function and slow the progression of disability

Side Effects: The Not-So-Fun Part

• Parkinson's medications can cause a range of side effects, depending on the specific drug and individual patient
  • L-dopa can cause nausea, vomiting, and dyskinesias (involuntary movements) at higher doses
  • Dopamine agonists can cause drowsiness, hallucinations, and impulse control disorders (gambling, hypersexuality)
  • MAO-B inhibitors can cause insomnia, headache, and gastrointestinal upset
  • Anticholinergics can cause dry mouth, constipation, urinary retention, and cognitive impairment, especially in older patients
• MS treatments also have potential side effects that need to be monitored and managed
  • Interferons can cause flu-like symptoms (fever, chills, fatigue) after injection, as well as depression and liver enzyme elevations
  • Glatiramer acetate can cause injection site reactions (redness, pain, swelling) and post-injection flushing
  • Natalizumab carries a risk of PML, a serious brain infection that requires close monitoring with MRI and JC virus antibody testing
  • Fingolimod can cause bradycardia (slow heart rate), macular edema (swelling in the retina), and rarely, PML
  • Dimethyl fumarate can cause flushing, gastrointestinal upset, and rarely, PML

Nursing Know-How: Administration Tips

• Parkinson's medications should be administered on a regular schedule to maintain consistent dopamine levels and optimize symptom control
  • L-dopa/carbidopa should be given 30-60 minutes before meals or 2 hours after meals to maximize absorption
  • Dopamine agonists and MAO-B inhibitors can be given with or without food
  • Anticholinergics should be started at low doses and titrated slowly to minimize side effects
• MS treatments require careful patient education and monitoring for side effects and treatment response
  • Interferons and glatiramer acetate are administered by subcutaneous or intramuscular injection, and patients should be taught proper injection technique and rotation of injection sites
  • Natalizumab is given by intravenous infusion every 4 weeks, and patients should be monitored for signs of PML (changes in cognition, vision, or motor function)
  • Oral medications like fingolimod and dimethyl fumarate require regular monitoring of blood work (liver enzymes, lymphocyte counts) and patient education on potential side effects

Real Talk: Patient Education and Support

• Patients with Parkinson's and MS face significant physical, emotional, and social challenges that require ongoing support and education
• Nurses play a key role in helping patients and their families understand the disease process, treatment options, and coping strategies
  • Encourage patients to stay active and engage in regular exercise, as this can help to maintain mobility, balance, and overall well-being
  • Provide resources for support groups, counseling, and occupational/physical therapy to help patients adapt to living with a chronic condition
• Medication adherence is crucial for optimal symptom management and disease control
  • Educate patients on the importance of taking medications as prescribed and reporting any side effects or concerns to their healthcare provider
  • Assist patients in developing strategies for remembering to take medications, such as using pill boxes, setting alarms, or enlisting the help of family members
• Emphasize the importance of regular follow-up with healthcare providers to monitor disease progression, adjust treatment plans, and address any new symptoms or concerns
  • Encourage patients to keep a symptom diary or log to track changes in their condition and share this information with their healthcare team
• Provide emotional support and validation for patients and their families, acknowledging the challenges they face and offering hope for effective management and improved quality of life